What it is
KLOW is a combination preparation, not a single molecule. The name descends from an earlier three-peptide blend marketed as GLOW (GHK-Cu, BPC-157, TB-500), with KPV added as a fourth component.
The four components:
BPC-157 is a fifteen-amino-acid peptide corresponding to a partial sequence of a protein found in human gastric juice.
TB-500 is a synthetic fragment of the actin-binding region of thymosin beta-4, a naturally occurring 43-amino-acid protein concentrated in platelets and wound fluid.
GHK-Cu is a copper-binding tripeptide — glycyl-L-histidyl-L-lysine complexed with copper(II). It has been studied for stimulation of extracellular matrix proteins including collagen, elastin, and glycosaminoglycans; for angiogenesis; for antioxidant activity through superoxide dismutase; and for anti-inflammatory effects including reduced TNF-α expression and suppression of NF-κB signaling.
KPV is the C-terminal tripeptide of α-melanocyte-stimulating hormone — lysine-proline-valine, residues 11–13. Preclinical work describes inhibition of NF-κB signaling and uptake into intestinal epithelium through the PepT1 transporter.
There is no standard KLOW formula. Concentrations vary between compounding pharmacies. A commonly marketed 80 mg vial contains 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-500, and 10 mg KPV, but that is a commercial convention rather than a validated dose derived from clinical study.
What the research shows
The single most important fact about KLOW is this: there are no controlled trials of the combination. Everything that can be said about it is inferred from four compounds studied separately, mostly in animals.
BPC-157. A 2025 systematic review in HSS Journal identified 36 studies in musculoskeletal healing — 35 animal, one human, the human study consisting of 12 uncontrolled patients.
TB-500. No completed randomized controlled trial exists for the fragment in humans. The human trials that are cited in its support used full-length thymosin beta-4 applied topically to wounds or to the eye, with mixed results across programs.
GHK-Cu. This has the strongest laboratory record of the four. Human dermal fibroblasts show increased collagen and elastin synthesis at nanomolar concentrations, and rodent wound models show accelerated epithelialization, improved collagen remodeling, and angiogenesis. But a 2025 review in the International Journal of Medical Sciences identified the absence of clinical trial data as the central limitation for GHK-Cu and related formulations. Almost all human experience with GHK-Cu is topical, not injected — which matters, because KLOW is injected.
KPV. The evidence is entirely preclinical. The most-cited work includes a Gastroenterology study describing PepT1-mediated uptake of KPV reducing intestinal inflammation in mouse colitis models, additional murine inflammatory bowel disease models, and an oral nanoparticle delivery study in mouse ulcerative colitis. There are no human randomized trials.
Combining four compounds does not sum their evidence. It compounds the uncertainty. There is no combination pharmacokinetic data, no information on interactions between the four, and — practically — no way to attribute an improvement or an adverse effect to any single component.
One component-specific consideration deserves its own mention: GHK-Cu delivers copper. Copper is an essential trace mineral with a relatively narrow tolerable range, and human safety data for repeated injected copper-peptide dosing is not established. Patients with Wilson disease or another disorder of copper metabolism, patients with liver disease, and patients already taking copper-containing preparations require particular scrutiny. That is one reason copper studies and liver function testing are part of the workup here rather than optional.
Who may be a candidate
- Adults with a combined picture — persistent soft-tissue or joint complaints alongside inflammatory or gastrointestinal symptoms — that has not responded to well-executed conventional care
- Post-surgical or post-injury patients whose recovery has plateaued and in whom a correctable structural cause has been excluded
- Patients under evaluation for chronic inflammatory symptoms in whom a specific diagnosis has already been pursued
- Patients who understand clearly that they are considering a four-compound investigational preparation with no trial data on the combination
It is generally not appropriate for patients with Wilson disease or another copper metabolism disorder, active or recent malignancy, significant hepatic or renal impairment, pregnancy or breastfeeding, drug-tested athletes and active-duty service members, or anyone unwilling to commit to monitoring.
What treatment looks like here
Evaluation. Full history, physical examination including osteopathic structural assessment, and review of prior imaging and records.
Laboratory work. Baseline testing typically includes a complete blood count, comprehensive metabolic panel with liver function, hs-CRP, hemoglobin A1c, vitamin D, iron studies and ferritin, thyroid function, and sex hormones where indicated. Because of the GHK-Cu component, serum copper, ceruloplasmin, and zinc are included at baseline and repeated on follow-up.
Route. KLOW is given by subcutaneous injection, since three of the four components are not meaningfully absorbed through skin.
Monitoring and simplification. Labs are repeated on a defined schedule, including copper indices, and progress is measured objectively against a stopping point agreed on in advance. The preference here is to simplify rather than stack.
FDA & regulatory status
KLOW is not an FDA-approved drug. It is a compounded combination, and none of its four components is FDA-approved for any of the uses discussed on this page.
BPC-157, TB-500, and KPV. All three were placed in Category 2 of the FDA’s 503A bulk drug substances review in 2023 — substances that may present significant safety risks — and all three were removed from Category 2 in April 2026. Removal did not add them to the 503A Bulks List; they default to unapproved-new-drug status. On July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee voted 8 to 6 with one abstention to recommend each of the three for inclusion on the 503A Bulks List — BPC-157 as nominated for ulcerative colitis, TB-500 for wound healing, and KPV for wound healing and inflammatory conditions. Those votes are advisory. The FDA is not bound by them, notice-and-comment rulemaking would have to be completed first, and inclusion on the Bulks List would not constitute FDA approval of the drug.
GHK-Cu. Its status is split by route. On the FDA’s bulk substances list updated May 14, 2026, GHK-Cu except for injectable routes of administration appears in Category 1, meaning it is still under evaluation. Injectable GHK-Cu was removed from Category 2 in April 2026 and is not on the 503A Bulks List. The FDA has stated it intends to consult the advisory committee regarding GHK-Cu before the end of February 2027. Because KLOW is injected, it is the injectable status that applies.
None of the four components appears on the 503B Bulks List, so none is available through an outsourcing facility.
For athletes and service members: BPC-157 has been prohibited by WADA under class S0 since January 2022, and TB-500 under class S2.3 since 2018, both in and out of competition. A blend containing them should be treated as prohibited.
Questions we get
If each peptide has been studied, doesn’t the blend inherit that evidence? No. Evidence attaches to what was actually tested. Four compounds studied separately in animals do not produce a studied combination in humans.
Why not use the blend anyway, since it is convenient? Convenience is real, and so is the cost. With four active compounds in one syringe, an improvement cannot be attributed and neither can a side effect. A single-agent trial usually teaches you more.
Is the copper in GHK-Cu a concern? It deserves attention rather than alarm. Copper, ceruloplasmin, and liver function are checked at baseline and on follow-up, and a copper metabolism disorder is a reason not to proceed.
Is KLOW FDA-approved, or legal? It is not FDA-approved. As of August 2026 none of its components is on the 503A Bulks List, and the injectable form of GHK-Cu is in the same unsettled position as the other three. An advisory committee recommended three of them for listing in July 2026, but the FDA has not completed the rulemaking that would give that effect.
Is it safe? That claim cannot responsibly be made about a four-compound preparation with no combination trial data. Anything used here is prescribed by a physician after individual evaluation, with laboratory monitoring including copper indices and scheduled reassessment.
Related
- 2 — Inflammation, Disease Risk & Prevention, the common thread across all four components
- 4 — Gut Health, where the KPV and BPC-157 animal literature is concentrated
- 8 — Muscle, Joint, Mobility & Pain, the most common reason patients ask
- 10 — Sleep, Recovery & Restoration, since repair capacity depends on it more than on any injectable
Next step
A blend is an easy thing to buy and a hard thing to interpret. The more useful starting point is an evaluation that establishes what is actually driving your symptoms — because in a meaningful number of cases the answer is a diagnosable condition, a mechanical problem, or a correctable deficiency, and none of those is best addressed with a four-peptide injection.
Candidacy for KLOW is determined by Dr. St. Marie through comprehensive evaluation and lab work. It is not appropriate for everyone.
To schedule, call 407-506-4776 or book online. Osteopathic Health of Orlando, 4625 Halder Lane, Suite C, Orlando, FL 32814.